Skip to ContentSkip to Navigation
About usNews and EventsNews articles

Health-economics of cardiovascular and renal disease prevention. From clinical trial to real-life settings

12 June 2009

PhD ceremony: C. Boersma, 13.15 uur, Academiegebouw, Broerstraat 5, Groningen

Thesis: Health-economics of cardiovascular and renal disease prevention. From clinical trial to real-life settings

Promotor(s): prof. M.J. Postma, prof. L.T.W. de Jong-van den Berg, prof. P.E. de Jong

Faculty: Mathematics and Natural Sciences


Cornelis Boersma evaluated in his thesis different epidemiological and health-economic aspects of preventive interventions in patients at increased cardiovascular and renal risk. In the last decades, cardiovascular and renal disease are leading causes of morbidity and mortality in the developed world resulting in enormous and growing burdens for health-care budgets. Therefore, prevention of cardiovascular disease events and prevention of progression to end-stage renal disease will remain very important. Currently, pharmacotherapeutic treatment is generally inititated in subjects with previous cardiovascular events or confirmed renal disease (secondary prevention). This re-active approach does not specifically identify the generally healthy subjects and is based on treatment of established risk-factors (e.g. hypertension, hypercholesterolemia, diabetes). Elevated albuminuria is more and more recognized as an early predictor of cardiovascular and renal disease in specific patient populations (e.g. diabetes, hypertension) and even in the general population. Next to the re-active approach, it has been suggested that active population-based screening for albuminuria could enable early identification and prevention of cardiovascular and renal disease.

In summary, it has been shown in this thesis that treatment with RAAS intervening agents (ARBs and ACE-inhibitors) in subjects at elevated cardiovascular and renal risk is likely to be cost-effective in preventing cardiovascular and/or renal diseases. Early intervention may be more optimal in that respect. Several studies in this thesis emphasize the importance of combining both clinical trial as well as observational data to support evidence-based decisions on health-care interventions and use of pharmacotherapeutic agents. Furthermore, the analyses in this thesis suggest potential favourable cost-effectiveness of active screening for (micro)albuminuria in the general population. These results were based on both data from clinical trials and observational data, and are therefore likely to be representative for ‘real-life’ settings. The results from this thesis ideally lead to increased awareness of the impact of albuminuria in clinical practice and offer health-care decisionmakers tools to seriously consider implementation of a population-based screening that is directed at albuminuria.


Last modified:15 September 2017 3.38 p.m.
printView this page in: Nederlands

More news

  • 14 October 2019

    Demonstrating that it can be done

    Moniek Tromp and Marleen Kamperman share a lot in common. Both are young professors of chemistry at the Zernike Institute for Advanced Materials (ZIAM).Both joined the UG in 2018. Both are engaged in developing new materials. Both enjoy promoting science...

  • 11 October 2019

    Down Under with Top Dutch

    After two years of hard work, the Groningen Top Dutch Solar Racing team has arrived in Australia. The team consists of students of the Hanze University of Applied Sciences, University of Groningen, and secondary vocational education (MBO) and is currently...

  • 11 October 2019

    Kick-off Young Science and Engineering Network (YSEN)

    Kick-off Young Science and Engineering Network (YSEN)